Provexis plc (AIM:PXS)

Market Cap	24.63M +57.4%
Revenue (ttm)	871.27K -27.4%
Net Income	-603.80K
EPS	-0.00
Shares Out	2.35B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	274,645
Open	1.122
Previous Close	1.050
Day's Range	0.928 - 1.122
52-Week Range	0.550 - 1.550
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2026

About Provexis

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product. The company sells its products through e-commerce website ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 2
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: PXS

Financial Performance

In fiscal year 2025, Provexis's revenue was 1.29 million, an increase of 61.13% compared to the previous year's 801,964. Losses were -452,720, -22.78% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error